Submitted 7 hours ago by vitalsign
Revolution Medicines has begun shipping experimental pancreatic cancer drug daraxonrasib and plans to submit it for FDA approval soon, according to CEO Mark Goldsmith.
A community for health content
222 subscribers
100% liked
Submitted by vitalsign to Health on 31 May 2026
Created by wellnoted, 3 months ago · stats
© 2026 Topicle Pty Ltd · Made in Melbourne, Australia
1 comment
Revolution Medicines has begun shipping experimental pancreatic cancer drug daraxonrasib and plans to submit it for FDA approval soon, according to CEO Mark Goldsmith.